HC Wainwright Issues Pessimistic Estimate for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a note issued to investors on Thursday, May 8th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.49) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a "Buy" rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at $0.78 EPS.

APLS has been the topic of several other research reports. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a report on Thursday, May 8th. Cantor Fitzgerald began coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 price objective on the stock. Raymond James downgraded Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and dropped their price objective for the company from $75.00 to $52.00 in a report on Friday, May 9th. Finally, Scotiabank decreased their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating for the company in a research report on Thursday, May 8th. Nine research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.42.

Apellis Pharmaceuticals Stock Up 6.3%

NASDAQ APLS traded up $1.03 during trading hours on Monday, hitting $17.39. 749,744 shares of the company were exchanged, compared to its average volume of 2,229,578. The company has a 50 day moving average of $20.48 and a two-hundred day moving average of $26.77. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $43.99. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -8.55 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $149.90 million for the quarter, compared to analysts' expectations of $197.61 million. During the same quarter last year, the company earned ($0.54) EPS. Apellis Pharmaceuticals's revenue for the quarter was down 3.2% compared to the same quarter last year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 6.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Granahan Investment Management LLC increased its position in Apellis Pharmaceuticals by 13.8% during the first quarter. Granahan Investment Management LLC now owns 175,696 shares of the company's stock worth $3,842,000 after buying an additional 21,278 shares in the last quarter. AQR Capital Management LLC increased its position in Apellis Pharmaceuticals by 119.6% during the first quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock worth $89,173,000 after buying an additional 2,220,977 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Apellis Pharmaceuticals during the first quarter worth $3,280,000. ADAR1 Capital Management LLC increased its position in Apellis Pharmaceuticals by 13.3% during the first quarter. ADAR1 Capital Management LLC now owns 17,000 shares of the company's stock worth $372,000 after buying an additional 2,000 shares in the last quarter. Finally, PDT Partners LLC boosted its holdings in shares of Apellis Pharmaceuticals by 41.7% during the first quarter. PDT Partners LLC now owns 195,165 shares of the company's stock worth $4,268,000 after purchasing an additional 57,471 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).